ClinicalTrials.gg
RecruitingNCT07122076Updated Sep 18, 2026

GT719 Injection for Moderate to Severe Refractory Autoimmune Diseases

An Early Phase 1 interventional study of GT719 Injection in Autoimmune Diseases, sponsored by Grit Biotechnology. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-18.

Sponsored by Grit Biotechnology · Early Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 125 studies in Autoimmune Diseases with a site in China — 72 open to participants now, 78 under way, 7 of them phase 3. Autoimmune Diseases · China.

Planned enrollment
95th of 113
10 · median 30
Started
2025
with 31 others
Phase 1
57 of 125
40 open now
Primary completion
2028-08
later than 58 of 77 live
Registered
95th of 125
by date
Lead sponsor
3 of 125
Grit Biotechnology

Among the 125 studies in Autoimmune Diseases with a site in China, this one is the 95th largest by planned enrollment of the 113 interventional ones that give a count, is one of 32 that started in 2025, is one of 57 in phase 1, reaches primary completion later than 58 of the 77 other live ones, and was the 95th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

72 of the 125 studies in Autoimmune Diseases with a site in China are open now. Recruiting first, the newest first:

67 more — sign in →

All 72 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 125 studies in Autoimmune Diseases with a site in China, or all of them as a file.
02

Study summary

This study is a prospective single-arm open-label clinical trial, aims to evaluate the safety, efficacy, and cellular pharmacokinetics of GT719 Injection in patients with moderate to severe refractory autoimmune diseases. A total of 10 subjects will be enrolled in this study.

03

Conditions studied

  • Autoimmune Diseases

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily enrolled in the study, signed an form, willing and able to comply with the study protocol.
  2. Aged 18 to 65 years (inclusive), regardless of gender.
  3. The functions of important organs meet the following requirements,excluding those attributable to disease activity:

    1. Bone marrow hematopoietic function needs to meet: ≥1×10\^9/L; ≥80g/L; ≥30×10\^9/L;
    2. Liver function: ≤3×; AST≤3×ULN; ≤1.5×ULN;
    3. Renal function: (CrCl) ≥30 ml/minute;
    4. Coagulation function: International standardized ratio () ≤1.5×ULN, prothrombin time (PT) ≤1.5×ULN;
    5. Heart function: good hemodynamic stability, with no evidence of moderate or greater pericardial effusion.
  4. Women of childbearing age must:

    1. During screening, the test result for serum β-human chorionic gonadotropin (β-hCG) was negative;
    2. Agree to avoid breastfeeding during the study period until at least one year after the infusion of GT719 cell injection or until two consecutive flow cytometry tests show the absence of GT719 cells (whichever occurs later);
    3. Male participants with sexual partners and female participants with potential fertility agree to use highly effective methods from screening until at least one year after GT719 cell injection or until two consecutive flow cytometry tests show the absence of GT719 cells (whichever occurs later). Male participants must agree to use condoms during sexual contact with pregnant or fertile women for at least one year after infusion of GT719 cell injection, even after successful vasectomy.

Specific inclusion criteria:

Systemic lupus erythematosus

  1. Complies with the classification standards of the 2019 European Union Against Rheumatology/American Society of Rheumatology (EULAR/ACR) SLE;
  2. Disease activity score SELENA SLEDAI≥6 with at least one Injima Lupus Assessment Group Index (BILAG-2004) category A (severe presentation) or two Category B (moderate presentation) organ scores, or both; Or disease activity score SELENA SLEDAI score ≥8;
  3. Definition of relapse : conventional treatment remains ineffective for more than 6 months or disease activity occurs again after remission. Conventional treatment is defined as the use of and cyclophosphamide, and any of the following immunomodulators: antimalarials, azathioprine, mortemycophanate, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab and telitacicept.

Inflammatory myopathy

  1. Inflammatory myopathy fulfilling the 2017 EULAR/ACR classification criteria (including Dermatomyositis (DM), Polymyositis (PM), Anti-Synthetase Syndrome (ASS), and Necrotizing Myopathy (NM)).
  2. Positive myositis antibodies;
  3. Muscle involvement with Manual Muscle Testing-8 (MMT-8) score less than 142 and at least two abnormalities found among the following five core measurements (Physician Global Assessment (PhGA), Patient Global Assessment (PtGA), or extramuscular disease activity score ≥ 2; Health Assessment Questionnaire (HAQ) total score ≥ 0.25; muscle enzyme levels ≥ 1.5×ULN; or MMT-8 ≥ 142, but with active interstitial lung disease (HRCT showing ground-glass opacities);
  4. Definition of relapsed/refractory: Conventional treatment over 6 months remains ineffective, or disease recurrence after remission. Definition of conventional treatment: the use of glucocorticoids and cyclophosphamide, and any one or more of the following immunomodulatory drugs: antimalarials, azathioprine, mycophenolate mofetil, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including belimumab, rituximab, and tocilizumab, etc.
  5. Definition of progressive: Rapid progression of interstitial lung disease within a short period.

Note: Meeting either criterion 4 or 5 is sufficient.

Diffuse systemic sclerosis

  1. Meet the 2013 ACR classification criteria for systemic sclerosis;
  2. Positive antibodies related to systemic sclerosis;
  3. Definition of relapse refractory: conventional treatment remains ineffective for more than 6 months or disease activity occurs again after remission. Conventional treatment is defined as the use of glucocorticoids and cyclophosphamide, and any of the following immunomodulators: antimalarials, azathioprine, mortemycophanate, methotrexate, leflunomide, tacrolimus, cyclosporine, and biologics including rituximab, belimumab and telitacicept
  4. Definition of progression: rapid skin progression (mRSS increase >25%); Or progression of lung disease (a 10% reduction in FVC, or a more than 5% reduction in FVC with a 15% reduction in DLCO).

Note: Articles 4 and 5 satisfy one or the other.

Exclusion criteria

Exclusion Criteria:

  1. SLE participants:

    1. Drug induced SLE;
    2. Patients with lupus crisis or concomitant diseases who require the use of drugs according to the protocol are deemed unsuitable for inclusion by the investigator.
  2. IIM participants

    1. Documented inclusion body myositis (IBM), drug-induced PM or DM, tumor associated PM or DM, non-inflammatory myopathy (such as muscular dystrophy);
    2. Uncontrolled extramuscular disease damage related to PM or DM:

    ILD: FVC\<55% or requiring oxygen therapy;

    Severe swallowing difficulties, as determined by investigator, increase the risk of patients participating in clinical trials;

    Severe cardiac manifestations (such as congestive heart failure, arrhythmia, conduction abnormalities requiring treatment, or myocardial infarction) have been determined by investigator to increase the risk of patients participating in clinical trials.

  3. SSc participants

    1. Moderate to severe pulmonary arterial hypertension (PAH) associated with SSc that cannot be controlled by drug therapy;
    2. Rapid progressive SSc related low gastrointestinal (small and large intestine) involvement (requiring parenteral nutrition); Active dilation of gastric antral blood vessels;
    3. Uncontrolled or rapidly progressing ILD with oxygen saturation (SaO2) \<92% (in still indoor air); Or require mechanical respiratory assistance (ventilator) within one year prior to signing the form.
  4. Has a history of severe reactions or allergies;
  5. Contraindications or hypersensitivity reactions to any components of fludarabine, cyclophosphamide, and experimental drugs;
  6. Suffering from the following heart diseases:

    1. Grade III or IV congestive heart failure;
    2. Has experienced a myocardial infarction or undergone coronary artery bypass surgery within the 6 months prior to the screening period;
    3. A history of ventricular arrhythmia or unexplained syncope, not caused by vasovagal nerve response or dehydration, or a interval (QTc)>480 ms during screening;
    4. History of severe non ischemic cardiomyopathy;
  7. Any active malignant tumors or history of malignant tumors within the past 5 years before screening. Excluding the following situations: early-stage tumors that have received curative treatment (in situ or stage I tumors, non ulcerative primary melanoma with a depth of\<1 mm and no involvement of lymph nodes), basal cell carcinoma of the skin, squamous cell carcinoma of the skin, cervical in situ cancer, or breast in situ cancer that has received potential curative treatment;
  8. Individuals with clinically significant bleeding symptoms or clear bleeding tendencies within the 6 months prior to screening, such as gastrointestinal bleeding, hemorrhagic gastric ulcers, etc; Hereditary or acquired bleeding and thrombophilia tendencies (such as hemophilia, coagulation dysfunction, splenic hyperfunction, etc.); Occurrence of arteriovenous thrombosis events within 6 months prior to screening, such as cerebrovascular disease (including cerebral hemorrhage, cerebral infarction, etc.), deep vein thrombosis, and/or pulmonary embolism;
  9. When screening, there may be serious underlying medical conditions, such as:

    1. There is evidence to suggest the presence of uncontrollable viruses, bacteria, fungi, or other infections that require systemic intravenous treatment;
    2. There is clear clinical evidence indicating the presence of dementia or changes in mental state;
    3. Any other history of central nervous system disorders or neurodegenerative diseases, such as epilepsy, seizures, paralysis, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, mental illness;
  10. Any of the following test results is positive:

    1. Positive for (HIV) antibodies;
    2. surface antigen (HBsAg) positive; Or if the hepatitis B core antibody (HBcAb) is positive and the hepatitis B virus (HBV) - DNA is higher than the detection limit of the analytical method;
    3. virus (HCV) antibody positive and HCV RNA above the detection limit of the analytical method;
    4. Syphilis antibody positive (false positive result due to reasons other than the disease);
  11. Cytomegalovirus (CMV) (DNA) and Epstein Barr virus (EBV) (DNA) tests positive;
  12. Active tuberculosis or latent tuberculosis without proper treatment before screening;
  13. Received other clinical trial drugs within 4 weeks prior to the signing of the informed consent form (ICF), or the ICF signing date is within 5 half lives of the drug from the last use of the drug in the previous clinical trial (whichever is longer);
  14. Received plasma exchange therapy or immunoadsorption therapy within 4 weeks prior to lymphodepleting chemotherapy;
  15. Used drugs targeting B cells, including but not limited to rituximab, belimumab, tacrolizumab, etc., within one week before lymphodepleting chemotherapy;
  16. Used tacrolimus, cyclosporine, azathioprine, mycophenolate mofetil, mycophenolate mofetil, methotrexate, etc. within 2 weeks before lymphodepleting chemotherapy;
  17. Used neonatal Fc receptor (FcRn) antagonist therapy (such as Efgartigimod) within 3 weeks before lymphodepleting chemotherapy;
  18. Within 3 weeks prior to lymphodepleting chemotherapy, complement inhibition therapy (such as Ecuzumab) has been used;
  19. Received attenuated within 4 weeks before lymphodepleting chemotherapy;
  20. Having undergone major surgery within the 8 weeks prior to screening, or planning to undergo surgery during the study period;
  21. Medical history of organ transplantation;
  22. Previously received CAR-T product therapy targeting any target (excluding GT719 therapy);
  23. According to the investigator's judgment, the situations that hinder participants from participating in the entire trial, confound the trial results, or participate in the trial that are not in the best interests of the participants.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    GT719 Injection treatment group

    GT719 Injection

    Biological: GT719 Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Proportion of participants experiencing dose limiting toxicity

    Proportion of participants experiencing dose limiting toxicity (DLT) within 28 days after cell infusion

    Time frame: 28 days

  2. Incidence of treatment-emergent adverse events

    Safety assessments are conducted using the NCI-CTCAE version 5.0 standards

    Time frame: 3 months

Secondary outcomes

  1. Efficacy outcomes for SLE

    SLE Response index 4(SR-4) response: Min/Max Value: Not specified; a decrease in score indicates improvment, higher scores indicate worse outcome

    Time frame: 14 days,1, 2, 3 and 6 Months post GT719 infusion

  2. Efficacy outcomes for Systemic Sclerosis

    ACR-CRISS score (CRISS score≥0.6 improvment, \<0.6 no improvement)

    Time frame: 14 days,1, 2, 3 and 6 Months post GT719 infusion

  3. Efficacy outcomes for Inflammatory Myopathy

    Total lmprovement Score (TlS): Min/Max Value: Not specified; an increase in score indicates improvement, higher scores indicate better outcome.

    Time frame: 14 days,1, 2, 3 and 6 Months post GT719 infusion

Other outcomes

  1. Efficacy outcomes for SLE

    SLE Response index 4(SR-4) response: Min/Max Value: Not specified; a decrease in score indicates improvment, higher scores indicate worse outcome

    Time frame: 12 weeks

  2. Efficacy outcomes for Systemic Sclerosis

    ACR-CRISS score (CRISS score≥0.6 improvment, \<0.6 no improvement)

    Time frame: 12 weeks

  3. Efficacy outcomes for Inflammatory Myopathy

    Total lmprovement Score (TlS): Min/Max Value: Not specified; an increase in score indicates improvement, higher scores indicate better outcome.

    Time frame: 12 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2028, 35 months after the start.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's planned 35 months is above that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 29, 2025
First posted
Aug 14, 2025
StartActual
Aug 22, 2025
Primary completionEst.
Aug 21, 2028
CompletionEst.
Aug 21, 2028
Last update
Sep 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07122076
Lead sponsor
Grit Biotechnology
Responsible party
Sponsor
First posted
Aug 14, 2025
Start date
Aug 22, 2025
Primary completion
Aug 21, 2028 (estimated)
Completion
Aug 21, 2028 (estimated)
Last update
Sep 18, 2026

Study contacts

Huji Xu
Contact
xuhuji@smmu.edu.cn
+86-21-81885514

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: GT719

Start the discussion